CNBC - Health
Forget Anthropic: In Europe, the IPO hype is about a blue lagoon
1 hour ago
As Pompe drug shortage drags on, patients struggle to get treatments1 hour ago
Novartis raises blockbuster drug forecasts as it seeks to prove growth can last12 hours ago
How this hedge fund is betting on people's fears of getting old23 hours ago
How the FDA built a case against executives promising cheap medications23 hours ago
Hims & Hers launches new slate of peptide treatments1 day ago
A generational flight from tech to defensive stocks is underway. How we're capitalizing2 days ago
U.S. officially loses measles elimination status amid ongoing outbreaks2 days ago
Novo says Wegovy injection lowers BMI and obesity rates in children in trial3 days ago
Feds arrest top healthcare company official, alleging illegal drug importation3 days ago
Measles is surging in the U.S. — and outbreaks can cost millions8 days ago
FDA warns of vision loss risk linked to GLP-1 drugs like Wegovy, Zepbound8 days ago
Eli Lilly's obesity pill eases sleep apnea in late-stage trial10 days ago
Could supplements be the next big opportunity in the GLP-1 weight-loss drug boom?10 days ago
Could CRISPR cure rare diseases before birth? Scientists are getting closer8 days ago
Moderna hikes 2026 sales growth outlook, smashes quarterly estimates8 days ago
Jim Cramer says the AI trade is not going away as Nasdaq enters correction14 days ago
CVS Health plans to split itself up. Here's why a breakup could make sense now15 days ago
Jim Cramer says this bank stock is a buy after its post-election pullback15 days ago
CVS falls on plans to split off drugstore business in major breakup15 days ago
Novo shares jump as Wegovy pill sales impress, drugmaker hikes outlook15 days ago
Pfizer hikes 2026 outlook as new products grow, taps company veteran as new CFO16 days ago
Midterm elections could jolt stocks as Democrats look poised to sweep Congress16 days ago
A biotech's high-stakes cancer bet just paid off and its shares doubled16 days ago
Jim Cramer says lower oil prices are giving stocks a boost. Can it last?16 days ago
Stocks started the week higher but ended in despair. Our take on the big reversal17 days ago
Cramer's week ahead: Expect more volatility as tech earnings, midterms loom20 days ago
Gen Z is ditching bars for run clubs — and finding more than friends along the way20 days ago
A pharma major is touting an MS drug to ease patent-cliff fears20 days ago
West Pharma: More than a GLP-1 play. The case for further upside21 days ago
Cramer sees opportunity amid tech turmoil and predicts a holiday win for FedEx21 days ago
Merck tops estimates, hikes profit outlook on strength of injectable Keytruda21 days ago
